Assessment of long-term COVID complications, increased fracture risk in diabetic patients

Diabetes is currently the eighth leading cause of death and disability worldwide, with approximately 500 million people suffering from the disease. The prevalence of diabetes is also expected to increase, with the total number of diagnosed cases estimated to reach 1.31 billion by 2050. As diabetes is a major public health concern worldwide, developing strategies to control risk factors is crucial.¹

At the Endocrine Society's 2024 Annual Meeting, held June 1-4 in Boston, Massachusetts, four posters were presented that delved deeper into diabetes, examining the effects of long COVID, increased fracture risk, the role of low-density lipoprotein (LDL) cholesterol in diabetes development, and the effectiveness of liraglutide in reducing cardiovascular complications.

For more ENDO 2024 coverage, click here

Pharmacy work is constantly changing. To stay ahead of the curve, Free Drug Topics Newsletter Get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.

References

1. GBD 2021 Diabetes Collaborators. Global, regional and national burden of diabetes from 1990 to 2021 and projections of prevalence to 2050: a systematic analysis from the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. PMID: 37356446; PMCID: PMC10364581.

2. Alieva A. Post-COVID-19 complications in diabetic patients are high 24 months after acute infection. Presentation location: ENDO 2024, June 1-4, 2024, Boston, MA.

3. Marion LA, Fremaint AI, Johannesdottir F, et al. “Contribution of skeletal microarchitecture and fall risk to fractures in adults with long-standing type 1 diabetes” Presentation location: ENDO 2024, 1-4 June 2024, Boston, MA.

4. Thiab G. Independent association of low LDL cholesterol levels with incident diabetes beyond the effect of statins. Presentation location: ENDO 2024, June 1-4, 2024, Boston, MA.

5. Del Rosario MP, Ong-Ramos C. A meta-analysis evaluating the efficacy of liraglutide in reducing cardiovascular complications in patients with type 2 diabetes. Presented at: ENDO 2024, June 1-4, 2024, Boston, MA.